Related Experiment Video

Updated: Oct 17, 2025

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

13.0K

Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated

Jae-Hyun Jang1, Donghwan Park1, Guen-Soo Park1

  • 1Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, Republic of Korea.

Experimental & Molecular Medicine
|October 12, 2021
PubMed

Insights

Mutant KRAS drives lung cancer by increasing leukotriene B4 receptor-2 (BLT2) and interleukin-6 (IL-6). Blocking BLT2 or its related enzymes reduced tumor growth, identifying BLT2 as a potential therapeutic target for KRAS-driven lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • KRAS mutations are prevalent in lung cancer, but their precise role in tumorigenesis is not fully understood.
  • Interleukin-6 (IL-6) is a key pro-inflammatory mediator implicated in lung cancer development.

Purpose of the Study:

  • To elucidate the mechanism by which KRAS mutations drive lung cancer.
  • To investigate the role of leukotriene B4 receptor-2 (BLT2) and its associated enzymes in KRAS-driven lung cancer.
  • To evaluate BLT2 as a potential therapeutic target for KRAS-driven lung cancer.

Main Methods:

  • Assessed the expression of BLT2 and 5-/12-lipoxygenase (LOX) in response to mutant KRAS.
  • Utilized pharmacological blockade of BLT2 or 5-/12-LOX in cell culture and KrasG12D transgenic mouse models.
  • Generated and analyzed KrasG12D/BLT2-knockout (KO) double-mutant mice.
  • Examined BLT2 expression in human lung adenocarcinoma tissue samples.

Main Results:

  • Mutant KRAS significantly upregulated BLT2 and 5-/12-LOX expression.
  • Inhibition of BLT2 or 5-/12-LOX attenuated KRAS-driven lung cell proliferation and IL-6 production.
  • BLT2 or 5-/12-LOX blockade reduced tumor formation in KrasG12D mice.
  • KrasG12D/BLT2-KO mice exhibited suppressed IL-6 production and lung tumor formation.
  • Elevated BLT2 expression was observed in human KrasG12D-positive lung adenocarcinoma tissues.

Conclusions:

  • BLT2 and its ligand-producing enzymes are upregulated by mutant KRAS and contribute to lung cancer development.
  • Targeting BLT2 or the 5-/12-LOX pathway offers a promising therapeutic strategy for KRAS-driven lung cancer.
  • BLT2 is a potential therapeutic target for KRAS-driven human lung cancer.

More Related Videos

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.5K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.8K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
679
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.3K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.5K